Why the study?
Does the combination of P2Y12/P2Y1 or P2Y12/thrombin inhibition synergistically reduce ADP- and thrombin-induced platelet activation in blood from healthy volunteers?
Does the combination of P2Y12/P2Y1 or P2Y12/thrombin inhibition synergistically reduce ADP- and thrombin-induced platelet activation in blood from healthy volunteers?
Dual inhibition of P2Y12/P2Y1 or P2Y12/thrombin demonstrates synergistic antiplatelet effects in vitro, providing a rationale for future clinical studies on combined antithrombotic therapies.
No takes yet. Share an insight, caveat, or question.
Offers in vitro rationale for dual inhibition; leaves open clinical translation and safety in patients.
Nylander et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: